Assembly Biosciences (ASMB) Curent Deferred Tax Liability (2014 - 2019)

Assembly Biosciences' Curent Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $3.3 million for Q1 2019.

• On a quarterly basis, Curent Deferred Tax Liability rose 52.26% year-over-year to $3.3 million in Q1 2019; TTM through Mar 2019 was $3.3 million, a 52.26% increase from a year earlier, with the FY2018 full-year figure at $3.3 million, up 52.25% from the prior year.
• Curent Deferred Tax Liability held at $3.3 million in Q1 2019 per ASMB's latest filing, from $3.3 million in the prior quarter.
• Across five years, Curent Deferred Tax Liability topped out at $11.6 million in Q1 2015 and bottomed at $2.1 million in Q3 2018.
• The 5-year median for Curent Deferred Tax Liability is $11.1 million (2017), against an average of $8.3 million.
• Across the five-year window, Curent Deferred Tax Liability tumbled 81.13% in 2018 and surged 52.26% in 2019, its largest moves.
• Year by year, Curent Deferred Tax Liability stood at $11.6 million in 2015, then dropped by 4.14% to $11.1 million in 2016, then slumped by 80.79% to $2.1 million in 2017, then soared by 52.25% to $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019.
• Per Business Quant, the three latest ASMB Curent Deferred Tax Liability figures stand at $3.3 million (Q1 2019), $3.3 million (Q4 2018), and $2.1 million (Q3 2018).